ULTRAGENYX PHARMACEUTICAL INC. Increase (Decrease) in Inventories
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Increase (Decrease) in Inventories of $7.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $3.00M.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $4.00M, a 300.00% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was -$150.00K, a 106.67% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was $5.15M, a 106.00% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for fiscal 2025 was $6.00M, a 45.45% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for fiscal 2024 was $11.00M, a 57.14% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for fiscal 2023 was $7.00M, a 27.84% decline from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. increase (decrease) in inventories for fiscal 2022 was $9.70M, a 211.23% increase from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 3 month as first filed | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 6 month as first filed | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month | Increase (Decrease) in Inventories 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $7.00M 10-Q · filed 2026-08-05 | $6.85M derived: sum of 3 quarters · filed 2026-08-05 | $12.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $4.00M 10-Q · filed 2026-05-06 | $3.85M derived: sum of 2 quarters · filed 2026-05-06 | $9.00M derived: sum of 3 quarters · filed 2026-05-06 | $9.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $5.00M derived: sum of 2 quarters · filed 2026-02-18 | $5.00M derived: sum of 3 quarters · filed 2026-08-05 | $6.00M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | $5.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.15M derived: sum of 2 quarters · filed 2026-08-05 | $6.15M 10-Q · filed 2025-11-05 | $8.40M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.00M 10-Q · filed 2026-08-05 | $555.00K 10-Q · filed 2025-08-06 | $3.25M derived: sum of 3 quarters · filed 2026-08-05 | $5.75M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $1.00M 10-Q · filed 2026-05-06 | $763.00K 10-Q · filed 2025-05-07 | $3.25M derived: sum of 2 quarters · filed 2026-05-06 | $5.75M derived: sum of 3 quarters · filed 2026-05-06 | $9.88M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $4.75M derived: sum of 2 quarters · filed 2026-02-18 | $8.88M derived: sum of 3 quarters · filed 2026-02-18 | $11.00M 10-K · filed 2026-02-18 | $11.21M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.63M derived: sum of 2 quarters · filed 2025-11-05 | $8.75M 10-Q · filed 2025-11-05 | $10.78M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-06-30 | $4.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $6.25M 10-Q · filed 2025-08-06 | $8.28M derived: sum of 3 quarters · filed 2026-02-18 | $11.74M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-03-31 | $2.12M 10-Q · filed 2025-05-07 | $4.15M derived: sum of 2 quarters · filed 2026-02-18 | $7.62M derived: sum of 3 quarters · filed 2026-02-18 | $9.27M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2023-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $5.49M derived: sum of 2 quarters · filed 2026-02-18 | $7.15M derived: sum of 3 quarters · filed 2026-02-18 | $7.00M 10-K · filed 2026-02-18 | $6.93M 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $3.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $5.12M derived: sum of 2 quarters · filed 2024-11-06 | $4.97M 10-Q · filed 2024-11-06 | $9.18M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $1.51M 10-Q · filed 2024-08-02 | $5.71M derived: sum of 3 quarters · filed 2025-02-19 | $6.50M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | -$150.00K 10-Q · filed 2024-05-03 | $4.05M derived: sum of 2 quarters · filed 2025-02-19 | $4.85M derived: sum of 3 quarters · filed 2025-02-19 | $8.08M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $5.00M derived: sum of 2 quarters · filed 2025-02-19 | $8.23M derived: sum of 3 quarters · filed 2025-02-19 | $9.70M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $791.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $4.02M derived: sum of 2 quarters · filed 2023-11-03 | $5.50M 10-Q · filed 2023-11-03 | $6.49M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | $3.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $4.71M 10-Q · filed 2023-08-04 | $5.70M derived: sum of 3 quarters · filed 2024-02-21 | $5.65M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | $1.48M 10-Q · filed 2023-05-05 | $2.46M derived: sum of 2 quarters · filed 2024-02-21 | $2.42M derived: sum of 3 quarters · filed 2024-02-21 | $5.07M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $990.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $943.00K derived: sum of 2 quarters · filed 2024-02-21 | $3.59M derived: sum of 3 quarters · filed 2024-02-21 | $3.12M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | -$47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.60M derived: sum of 2 quarters · filed 2022-11-03 | $2.13M 10-Q · filed 2022-11-03 | $838.00K derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-06-30 | $2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $2.17M 10-Q · filed 2022-07-29 | $885.00K derived: sum of 3 quarters · filed 2023-02-17 | $4.04M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-03-31 | -$474.00K 10-Q · filed 2022-05-06 | -$1.76M derived: sum of 2 quarters · filed 2023-02-17 | $1.39M derived: sum of 3 quarters · filed 2023-02-17 | $1.02M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2020-12-31 | -$1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $1.87M derived: sum of 2 quarters · filed 2023-02-17 | $1.50M derived: sum of 3 quarters · filed 2023-02-17 | $1.35M 10-K · filed 2023-02-17 | |||
| 2020-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $2.78M derived: sum of 2 quarters · filed 2021-11-03 | $2.63M 10-Q · filed 2021-11-03 | $482.00K derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-06-30 | -$372.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | -$521.00K 10-Q · filed 2021-08-03 | -$2.67M derived: sum of 3 quarters · filed 2022-02-15 | -$2.11M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-03-31 | -$149.00K 10-Q · filed 2021-05-05 | -$2.30M derived: sum of 2 quarters · filed 2022-02-15 | -$1.74M derived: sum of 3 quarters · filed 2022-02-15 | $655.00K derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2019-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$1.59M derived: sum of 2 quarters · filed 2022-02-15 | $804.00K derived: sum of 3 quarters · filed 2022-02-15 | $4.45M 10-K · filed 2022-02-15 | |||
| 2019-09-30 | $564.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $2.96M derived: sum of 2 quarters · filed 2020-10-27 | $6.60M 10-Q · filed 2020-10-27 | $7.09M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-06-30 | $2.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $6.04M 10-Q · filed 2020-07-30 | $6.52M derived: sum of 3 quarters · filed 2021-02-12 | $8.74M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-03-31 | $3.65M 10-Q · filed 2020-05-07 | $4.13M derived: sum of 2 quarters · filed 2021-02-12 | $6.34M derived: sum of 3 quarters · filed 2021-02-12 | $7.62M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2018-12-31 | $484.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $2.70M derived: sum of 2 quarters · filed 2021-02-12 | $3.97M derived: sum of 3 quarters · filed 2021-02-12 | $5.28M 10-K · filed 2021-02-12 | |||
| 2018-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $3.49M derived: sum of 2 quarters · filed 2019-11-06 | $4.80M 10-Q · filed 2019-11-06 | ||||
| 2018-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $2.58M 10-Q · filed 2019-08-02 | |||||
| 2018-03-31 | $1.31M 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | $757.00K 10-K · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |